title: Characteristics of children with the best and poorest first- and second-year growth during rhGH therapy: data from 25 years of the Genentech national cooperative growth study (NCGS).
abstract: BACKGROUND
  Models assessing characteristics contributing to response to recombinant human growth hormone (rhGH) response rarely address growth extremes in both years 1 and 2 or examine how children track from year to year. Using National Cooperative Growth Study (NCGS) data, we determined characteristics contributing to responsiveness to rhGH and the pattern of change from years 1 to 2.
  
  
  METHODS
  Height velocity standard deviation score (HV SDS) for 2 years for prepubertal children with idiopathic GH deficiency (IGHD) (n = 1899) and idiopathic short stature (ISS) (n = 1186) treated with similar doses for two years were computed. Group 1 = HV SDS < -1; 2 = HV SDS -1 to +1; 3 = HV SDS > +1.
  
  
  RESULTS
  For IGHD, mean age was 7.5 years and similar in all groups. Year 1 HV SDS was associated with greater body mass index (BMI) SDS, lower pre-treatment HV, baseline height SDS, greater target height SDS minus height SDS, and lower maximum stimulated GH (P <0.0001). Year 2, 172/271 (73%) in group 1 moved to either group 2 (n = 156) or 3 (n = 16). Year 2 HV SDS was associated with greater year 1 HV SDS (r = 0.045, P <0.0001), greater BMI SDS, taller parents and lower peak GH.For ISS, year 1 HV SDS was associated with greater BMI SDS and lower pre-treatment HV (P ≤0.0001). 109/169 (64%) in group 1 moved to group 2 (n = 90) or group 3 (n = 19). Greater year 2 HV SDS was related to year 1 HV SDS (r = 0.27, P <0.0001).
  
  
  CONCLUSIONS
  For IGHD, multiple characteristics contributed to best first-year response but for ISS, best first-year HV SDS was associated only with BMI SDS and inversely with pre-treatment HV. For both GHD and ISS, year 1 HV SDS was not a strong enough predictor of year 2 HV SDS to use first-year HV alone to determine GH continuation.
authors: Endocrinology, Children's National Medical Center, George Washington University School of Medicine & Health Sciences, Washington, DC, USA. PKaplowi@childrensnational.org.
authors: Paul B
authors: PB
authors: Kaplowitz
authors: Dorothy I
authors: DI
authors: Shulman
authors: James W
authors: JW
authors: Frane
authors: Joan
authors: J
authors: Jacobs
authors: Barbara
authors: B
authors: Lippe
references: Arch Dis Child. 1995 Sep;73(3):277
references: 7492183
references: Int J Pediatr Endocrinol. 2011 Jul 07;2011:6
references: 21899782
references: J Pediatr Endocrinol Metab. 2000;13 Suppl 6:1365-9
references: 11202211
references: J Clin Endocrinol Metab. 2008 Feb;93(2):352-7
references: 18000092
references: Acta Paediatr. 1998 Apr;87(4):387-91
references: 9628292
references: Growth Horm IGF Res. 2009 Feb;19(1):1-11
references: 18824380
references: Horm Res. 2007;68 Suppl 5:51-6
references: 18174708
references: Acta Paediatr. 1995 Jan;84(1):51-7
references: 7734899
references: Horm Metab Res. 1998 Sep;30(9):565-9
references: 9808325
references: Arch Dis Child. 1966 Dec;41(220):613-35
references: 5927918
references: J Clin Endocrinol Metab. 1998 Aug;83(8):2735-41
references: 9709940
references: Eur J Pediatr. 2002 May;161(5):250-4
references: 12012218